Skip to main content

13 Result(s)

within L. P. Koh Remove this filter

and

  1. No Access

    Article

    Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma

    A patient with advanced and chemotherapy-refractory nodal marginal zone B-cell lymphoma was given a course of chimeric CD 20 monoclonal antibody Rituximab. Partial response was observed without any major toxic...

    L-P Koh, L-C Lim, C-H Thng in Medical Oncology (2000)

  2. No Access

    Article

    Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis

    The main obstacles to successful hematopoietic stem cell transplantation for patients with chronic myeloid leukemia (CML) in blast crisis (BC) are increased post-transplant relapse and high treatment-related m...

    L P Koh, W Y K Hwang, C T H Chuah, Y C Linn, Y T Goh… in Bone Marrow Transplantation (2003)

  3. No Access

    Article

    Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin

    An end-stage renal failure patient with lupus nephritis was treated with low molecular weight heparin (LMWH) and aspirin for cardiac ischemia. She was then subjected to surgery to recreate a new arteriovenous ...

    H. J. Ng, L. P. Koh, L. H. Lee in Annals of Hematology (2003)

  4. No Access

    Article

    Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling—evaluation of risks and benefits

    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for patients with chronic myeloid leukemia (CML), but is associated with significant morbidity and mortality. The re...

    L. P. Koh, W. Y. K. Hwang, C. H. Tan, Y. C. Linn, Y. T. Goh… in Annals of Hematology (2004)

  5. No Access

    Article

    A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation

    We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifo...

    W Y K Hwang, L-P Koh, H J Ng, P H C Tan, C T H Chuah… in Bone Marrow Transplantation (2004)

  6. No Access

    Article

    Haploidentical hematopoietic cell transplantation

    Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients to benefit from HCT when a HLA genotypically matched sibling is not available. Initial results with...

    L-P Koh, N Chao in Bone Marrow Transplantation (2008)

  7. No Access

    Article

    Stem cell transplantation programme at Singapore General Hospital

    The adult transplant programme at Singapore General Hospital (SGH) was established in 1985 and more than 820 transplants have been performed to date. An average of about 60 adult transplants (autologous and al...

    M B C Koh, Y T Goh, P H C Tan, L P Koh, W Y K Hwang, Y Loh… in Bone Marrow Transplantation (2008)

  8. No Access

    Article

    Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib

    L-M Poon, L P Koh in Bone Marrow Transplantation (2012)

  9. No Access

    Article

    Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group

    Eighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced ...

    E Tse, T S Y Chan, L-P Koh, W-J Chng, W-S Kim, T Tang… in Bone Marrow Transplantation (2014)

  10. No Access

    Article

    Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group

    The clinical outcome of multiple myeloma is heterogeneous. Both the depth of response to induction and transplant as well as early relapse within a year are correlated with survival, but it is unclear which fa...

    S Y Ong, S de Mel, Y X Chen, M G Ooi, S Surendran, A Lin… in Bone Marrow Transplantation (2016)

  11. No Access

    Article

    An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication

    The refined disease risk index (DRI) is a powerful prognostic model based solely on the disease type and stage for predicting survival outcomes of various hematological malignancies after allogeneic transplant...

    V V Maka, L-P Koh, C Diong, Y-T Goh, S Gopalakrishnan, A Ho… in Bone Marrow Transplantation (2017)

  12. No Access

    Article

    Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore

    M B Abid, D Christopher, M A Abid, M L Poon, L K Tan… in Bone Marrow Transplantation (2017)

  13. No Access

    Article

    Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis

    There is currently no consensus on the role of upfront autologous transplantation (ASCT) for patients with peripheral T-cell lymphomas (PTCL), especially in patients achieving first complete remission (CR1) fo...

    L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan… in Bone Marrow Transplantation (2024)